Dalpiciclib vs Palbociclib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HR+/HER2- Metastatic Breast Cancer

Shared mechanism: CDK4 and CDK6 · full HR+/HER2- Metastatic Breast Cancer pipeline

Dalpiciclib

Marketed by Jiangsu Hengrui Pharmaceuticals

Phase 3 in HR+/HER2- Metastatic Breast Cancersmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: December 2026 · NCT04993430 (registry estimate)

No aligned efficacy figure on record for this race.

Palbociclib · Ibrance

Marketed by Pfizer

Approved in HR+/HER2- Metastatic Breast Cancersmall molecule
Reliable signal

NCT01740427 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled phase 3 trial with 666 participants. Its primary clinical endpoint, investigator-assessed progression-free survival using RECIST criteria, was significantly improved with palbociclib plus letrozole (hazard ratio 0.576; p<0.000001), supporting a strong evidence grade.

Next expected readout: November 2026 · NCT02605486 (registry estimate)

Reported efficacy

Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6) (met)

Result source: NCT02297438

Results for HR+/HER2- Metastatic Breast Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointDalpiciclibPalbociclib
PFS, median—Trial running · NCT0661281424.8 vs 14.5+10.3 vs placebon 444NCT01740427
20 other results
OS, median—Trial running · NCT0661281453.9 vs 51.2+2.7 vs placebon 444NCT01740427
14 other results
ORR—Trial running · NCT0661281446.4% vs 38.3%+8.1 vs placebon 444NCT01740427
15 other results
Clinical benefit rate—Trial running · NCT0661281485.8% vs 71.2%+14.6 vs placebon 444NCT01740427
10 other results

PFS, median

Dalpiciclib
—Trial running · NCT06612814
Palbociclib
24.8 vs 14.5+10.3 vs placebon 444NCT01740427
20 other results

OS, median

Dalpiciclib
—Trial running · NCT06612814
Palbociclib
53.9 vs 51.2+2.7 vs placebon 444NCT01740427
14 other results

ORR

Dalpiciclib
—Trial running · NCT06612814
Palbociclib
46.4% vs 38.3%+8.1 vs placebon 444NCT01740427
15 other results

Clinical benefit rate

Dalpiciclib
—Trial running · NCT06612814
Palbociclib
85.8% vs 71.2%+14.6 vs placebon 444NCT01740427
10 other results
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Dalpiciclib: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Dalpiciclib: 0 of 4 rows · Palbociclib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricPalbociclib
Dropout rate
n/a: no completion milestonea
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 55 more results
n/a: no completion milestone
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
n/a: no completion milestone
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
69.1%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
34%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestoneCohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
0%
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
1.1%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
87.5%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
1.1%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
0%
NCT02668666 · Phase 2 · registry result, not featured evidence
1.4%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
1.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
1.6%
NCT02536742 · Phase 2 · registry result, not featured evidence
12.5%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
2.6%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
2.8%
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
0%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
n/a: no completion milestone125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
100%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
97.6%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
n/a: no completion milestone300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
n/a: no completion milestone25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
n/a: no completion milestone
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
0%Fulvestrant + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%Tamoxifen + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
n/a: no completion milestone5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
Discontinued due to AEs
7.2%a
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 55 more results
8.9%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
—
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
3.9%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
2%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
5.2%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
2%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
2.3%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
—
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
—
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
—
NCT02668666 · Phase 2 · registry result, not featured evidence
—
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
—
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
—
NCT02536742 · Phase 2 · registry result, not featured evidence
—Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
—T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
—125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
—100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
—125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
16.7%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
—Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
0%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
15.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
—300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
—25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
—125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
—100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
11.5%
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
—Fulvestrant + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—Tamoxifen + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
—8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
50%8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
33.3%6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
0%5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
Serious AEs
28.2%a
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 55 more results
22.6%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
20.2%
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
29.6%Palbociclib+Letrozole Australia Co
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
18%Palbociclib+Letrozole India Cohort
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
22.7%Cohort 1: Palbociclib Plus Exemest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
14.1%Cohort 2: Palbociclib Plus Fulvest
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
24.6%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
—
NCT02692755 · Phase 2/3 · registry result, not featured evidence · combination
38%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
15.7%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
13.5%125mg
NCT02630693 · Phase 2 · registry result, not featured evidence
10%100mg
NCT02630693 · Phase 2 · registry result, not featured evidence
32.7%
NCT02668666 · Phase 2 · registry result, not featured evidence
54.2%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
27.8%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
73%
NCT02536742 · Phase 2 · registry result, not featured evidence
21.4%Single Agent T-DM1
NCT03530696 · Phase 2 · registry result, not featured evidence
21.1%T-DM1 With Palbociclib
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
—
NCT03691493 · Phase 2 · registry result, not featured evidence · combination
5.9%125mg
NCT02384239 · Phase 2 · registry result, not featured evidence
13.9%100mg
NCT02384239 · Phase 2 · registry result, not featured evidence
0%125 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
9.5%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
33.3%125 mg + 2.5 mg
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
0%100 mg
NCT01684215 · Phase 2 · registry result, not featured evidence
30.3%Ph2P1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
24%Ph2P2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
16.7%Phase 1 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
26.5%Phase 2 (Palbociclib + Letrozole)
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20%300 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
33.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%150 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
13.3%150 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
33.3%100 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
16.7%75 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%75 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
0%50 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
11.1%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
0%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
12%50 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
20%25 mg BID
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
40%25 mg QD
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
100%125mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
83.3%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
87.5%100mg
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
15.4%
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
40%Fulvestrant + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
0%Tamoxifen + Palbociclib
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
25%8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—8 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
16.7%6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—6 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
33.3%5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
—5 mg
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
Most frequent reported AEs
a
neutropenia 69.4% (placebo 3.6%)
arthralgia 42.1% (placebo 40.1%)
fatigue 41.2% (placebo 29.3%)
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 49 more results
neutropenia 67%
fatigue 43.8%
nausea 36.5%
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutrophil count decreased 66.7% (placebo 11.1%)
white blood cell count decreased 64.3% (placebo 9.9%)
neutropenia 44.6% (placebo 7%)
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
neutropenia 72.4%
fatigue 65.1%
nausea 37.5%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutropenia 57%
anaemia 22%
alopecia 17%
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
neutrophil count decreased 62.7%
fatigue 55.3%
hypertension 34%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 63.1%
fatigue 51%
hypertension 36.9%
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
neutropenia 70%
leukopenia 34.6%
anaemia 33.8%
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
neutrophil count decreased 92.4%
white blood cell decreased 87%
fatigue 84.8%
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
diarrhoea 92.2%
nausea 52.9%
stomatitis 41.2%
NCT04224272 · Phase 2 · registry result, not featured evidence · combination
125mg
fatigue 82%
nausea 53.9%
back pain 46.1%
NCT02630693 · Phase 2 · registry result, not featured evidence
100mg
fatigue 85.6%
nausea 52.2%
insomnia 48.9%
NCT02630693 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 71.4%
fatigue 65.3%
white blood cell decreased 65.3%
NCT02668666 · Phase 2 · registry result, not featured evidence
diarrhea 65.3%
anemia 48.6%
platelet count decreased 38.9%
NCT03644186 · Phase 2 · registry result, not featured evidence · combination
white blood cell count decreased 96.3%
neutrophil count decreased 87%
anemia 79.6%
NCT03007979 · Phase 2 · registry result, not featured evidence · combination
nausea 57.1%
aspartate aminotransferase increased 50%
fatigue 50%
NCT03530696 · Phase 2 · registry result, not featured evidence
neutrophil count decreased 84.2%
platelet count decreased 76.3%
white blood cell count decreased 76.3%
NCT03530696 · Phase 2 · registry result, not featured evidence · combination
125mg
neutrophil count decreased 26.5%
hypertension 0%
NCT02384239 · Phase 2 · registry result, not featured evidence
100mg
neutrophil count decreased 13.9%
hypertension 5.6%
NCT02384239 · Phase 2 · registry result, not featured evidence
125 mg
white blood cell count decreased 83.3%
diarrhoea 66.7%
neutrophil count decreased 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence
125 mg + 2.5 mg
neutrophil count decreased 81%
stomatitis 76.2%
white blood cell count decreased 71.4%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
125 mg + 2.5 mg
neutrophil count decreased 100%
white blood cell count decreased 100%
diarrhoea 66.7%
NCT01684215 · Phase 2 · registry result, not featured evidence · combination
100 mg
neutrophil count decreased 83.3%
white blood cell count decreased 66.7%
aspartate aminotransferase increased 33.3%
NCT01684215 · Phase 2 · registry result, not featured evidence
neutropenia 78.8%
leukopenia 48.5%
fatigue 42.4%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 72%
fatigue 40%
leukopenia 40%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 91.7%
fatigue 83.3%
leukopenia 66.7%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
neutropenia 74.7%
leukopenia 43.4%
fatigue 41%
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
300 mg QD
nausea 40%
fatigue 30%
headache 30%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
neutrophil count decreased 100%
anaemia 66.7%
fatigue 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
150 mg BID
abdominal pain 66.7%
ggt increased 66.7%
nausea 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
150 mg QD
nausea 40%
headache 26.7%
hypertension 26.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
100 mg QD
white blood cell count decreased 91.7%
neutrophil count decreased 58.3%
anaemia 41.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
100 mg QD
abdominal pain upper 33.3%
arthralgia 33.3%
back pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg BID
arthralgia 33.3%
fall 33.3%
fatigue 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
75 mg QD
hypophosphataemia 66.7%
blood alkaline phosphatase increased 33.3%
breast pain 33.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg BID
alt increased 50%
anaemia 50%
cough 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
neutrophil count decreased 77.8%
white blood cell count decreased 77.8%
anaemia 66.7%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
50 mg QD
fatigue 25%
ggt increased 18.8%
arthralgia 12.5%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
50 mg QD
ggt increased 14.7%
covid-19 10.7%
ast increased 9.3%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · monotherapy
25 mg BID
nausea 60%
neutrophil count decreased 60%
white blood cell count decreased 60%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
25 mg QD
neutrophil count decreased 80%
white blood cell count decreased 70%
anaemia 50%
NCT03560531 · Phase 1/2 · registry result, not featured evidence · combination
125mg
mucositis oral 100%
neutrophil count decreased 100%
platelet count decreased 100%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 100%
neutrophil count decreased 83.3%
fatigue 50%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
100mg
mucositis oral 96.9%
neutrophil count decreased 87.5%
fatigue 65.6%
NCT02871791 · Phase 1/2 · registry result, not featured evidence · combination
neutrophil count decreased 61.5%
platelet count decreased 57.7%
white blood cell count decreased 57.7%
NCT02499146 · Phase 1 · registry result, not featured evidence · combination
dyspnea 60%
neutrophil count decreased 60%
skin and subcutaneous tissue disorders - other 60%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
blood and lymphatic system disorders - other 50%
hypertension 50%
neutrophil count decreased 50%
NCT02913430 · Phase 1 · registry result, not featured evidence · combination
8 mg
diarrhea 75%
oral mucositis 75%
dry skin 50%
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
6 mg
fatigue 83.3%
oral mucositis 83.3%
dry mouth 66.7%
NCT03238196 · Phase 1 · registry result, not featured evidence · combination
5 mg
anemia 100%
constipation 100%
dry skin 100%
NCT03238196 · Phase 1 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 53 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Palbociclib

PFS 24.8 vs 14.5 placebo months
time to event · months
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 9 more results
9.2 vs 3.8 Fulvestrant months
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
21.5 vs 13.9 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
21.6 vs 16.4 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
7.3 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
7.5 vs 9.4 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
8 vs 10.6 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
20.2 vs 10.2 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
26.1 vs 10.2 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
18.1 vs 10.2 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
ORR 46.4% (n=444) vs 38.3% (n=222) placebo
responder rate · % of participants
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 11 more results
21% (n=347) vs 8.6% (n=174) Fulvestrant
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
37.3% (n=169) vs 31.6% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
43.4% (n=145) vs 38% (n=142) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
40.2% (n=169) vs 33.9% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
52.3% (n=128) vs 43.5% (n=131) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
42.9% (n=84) vs 33.3% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
44.1% (n=34) vs 33.3% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
42% (n=50) vs 33.3% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
55.4% (n=65) vs 39.4% (n=66) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
55.6% (n=27) vs 39.4% (n=66) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
55.3% (n=21) vs 39.4% (n=66) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
Duration of Response 20.1 vs 16.7 placebo months
time to event · months
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 7 more results
10.4 vs 9 Fulvestrant months
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
22.4 vs 19.4 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
30.3 vs 24.9 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
9.7 vs 11.2 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
20.3 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.9 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
20.2 vs 11.1 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
Clinical Benefit 85.8% (n=444) vs 71.2% (n=222) placebo
responder rate · % of participants
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 8 more results
66.3% (n=347) vs 39.7% (n=174) Fulvestrant
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
79.3% (n=169) vs 80.1% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
77.9% (n=145) vs 79.6% (n=142) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
76.9% (n=169) vs 73.1% (n=171) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
78.1% (n=128) vs 71.8% (n=131) placebo
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
81% (n=84) vs 58% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
76.5% (n=34) vs 58% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
84% (n=50) vs 58% (n=81) Letrozole
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
Overall Survival 53.9 vs 51.2 placebo months
time to event · months
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
show 8 more results
53.8 vs 49.8 placebo months
NCT01740427 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
34.9 vs 28 Fulvestrant months
NCT01942135 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
51.7 vs 51.5 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
50.3 vs 49.7 placebo months
NCT02297438 · Phase 3 · combination · Breast Cancer, HR+/HER2- Metastatic Breast Cancer · phase 3
33.7 vs 32 Capecitabine months
NCT02028507 · Phase 3 · registry result, not featured evidence · combination
37.5 vs 34.5 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
37.5 vs 34.5 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
35.1 vs 34.5 Letrozole months
NCT00721409 · Phase 2 · registry result, not featured evidence · combination
Complete 1% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
1.3% (n=152)
Percentage of participants with complete response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
Partial 28% (n=100)
responder rate · % of participants
No placebo or comparator arm
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
11.8% (n=152)
Percentage of participants with partial response
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
ORR 29% (n=100)
absolute value · percentage points
No placebo or comparator arm
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
show 3 more results
13.2% (n=152)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
24.8% (n=129)
NCT02600923 · Phase 3 · registry result, not featured evidence · combination
55% (n=47)
NCT03633331 · Phase 2 · registry result, not featured evidence · combination
EQ-5D Utility 0.698 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D Utility -0.147 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D-VAS 73.6 score
absolute value · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination
EQ-5D VAS -3.2 score
absolute change · score
No placebo or comparator arm
End of Treatment (EOT)
NCT02679755 · Phase 4 · registry result, not featured evidence · combination

+ 77 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dalpiciclib's landscape · Palbociclib's landscape